| ID | 10034 |
| Vaccine Name | MVC-COV1901 |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Protein subunit |
| Vaccine Status | Approved |
| Manufacturer | Medigen Vaccine Biologics, Dynavax |
| Year of Manufacturing | 2021 |
| Manufacturing Country | Taiwan |
| Age | 12 years and above |
| Dosage | 2 doses 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | CpG 1018, aluminium hydroxide |
| Target Strain | S-2P protein |
| Description | NA |
| Approving Organisation | Taiwan FDA |
| Collaborating Organisation | National Institute of Allergy and Infectious Diseases |
| Other Countries | Thailand, Taiwan, Paraguay |
| Trade Name | NA |
| PMID | 33816047 |
| Clinical Trial ID | NCT05198596 |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003899/ |
| Additional Links | https://www.precisionvaccinations.com/vaccines/medigen-covid-19-vaccine
|